Le Lézard
Classified in: Health, Science and technology

BioGX Candida Auris PCR Assay Adoption Accelerates

BIRMINGHAM, AL / ACCESSWIRE / March 23, 2023 / BioGX, a global provider of easy molecular diagnostic solutions, announced accelerated adoption of their high performance Sample-Ready™ PCR assay* for detection of Candida auris, a rapidly spreading, hard to treat fungus with a growing presence in hospitals and long-term care facilities. A complete PCR mix is provided in a single lyophilized tube format to be validated by laboratories on a variety of real-time PCR instruments including the BD MAX™, ThermoFisher QuantStudio™, BioRAD CFX Touch™ and the new BioGX pixl™ platform.

"Our platform agnostic Candida auris PCR assay has been successfully validated and implemented by public health laboratories and hospitals in several states," said Shahin Iqbal, PhD, BioGX President & COO." He further added, "We are grateful that laboratories trust us to address their unmet needs for detection of emerging pathogens."

Dr. Margie Morgan, Director, Clinical Microbiology Pathology and Laboratory Medicine at Cedars Sinai Hospital said "the BioGX Candida auris PCR assay provides a rapid and sensitive method to perform surveillance testing for our patient population. The real time results have been used by our Epidemiology team to institute timely isolation precautions to successfully prevent C. auris transmission in our medical center."

BioGX's Sample-Ready™ line of products offer custom manufactured or Research Use Only PCR assays, lyophilized in a single vial and fine-tuned to ensure high performance across multiple platforms that are commonly used in laboratories today.

Additional information can be requested by contacting BioGX at Ph: + or [email protected].

*Research Use Only, Not intended for human or animal diagnostic use.

Sample-Ready, Just Add Water, Xfree and pixl are trademarks of BioGX, Inc.

About BioGX

BioGX is a leading global provider of lyophilized real-time PCR reagents for molecular diagnostics. BioGX, Inc., headquartered in Birmingham, Alabama and Dallas, TX, and its wholly owned subsidiary BioGX B.V., based in Amsterdam, The Netherlands, (collectively "BioGX"), operates in a cGMP compliant environment certified to ISO 13485 medical device development and manufacturing standards. For more information, visit BioGX.com.

Contact Information:

Mohammed Merchant
Sr. Director, Marketing
[email protected]
(205) 250-8055



View source version on accesswire.com:

These press releases may also interest you

at 14:20
GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced results from a retrospective analysis of the interventional PATHFINDER study to assess whether diagnostic evaluations of individuals who...

at 14:15
Gracell Biotechnologies Inc. ("Gracell" or the...

at 14:15
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class...

at 13:35
Gilead Sciences, Inc. and Arcus Biosciences, Inc. today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ?50%...

at 12:17
Sanctuary Cannabis, a trusted provider of high-quality medical cannabis products, is excited to announce the grand opening of its 19th medical cannabis dispensary in Boynton Beach, Florida....

at 12:00
?  PRGN-2009 combined with an investigational checkpoint inhibitor resulted in a 30% ORR in patients with heavily pre-treated HPV-associated cancers that were naïve or resistant to checkpoint blockade with prolonged duration of responses?? ? ...

News published on and distributed by: